Vericel Corp.
Company Snapshot
Founded: 1989
Entity Type: Public
Employees: 375
Region: U.S.
Revenue: $237.2 Millions
Revenue Year: 2024
Headquarter: Massachusetts, U.S.
Key Geographics: North America
Corporate Address: 64 Sidney Street Cambridge Massachusetts-02139 U.S. Tel. +1-(617)-588-5555 www.vcel.com
Company Overview
Vericel Corp. is a fully integrated, biopharmaceutical company known for its advanced therapies catering to the sports medicine and severe burn care sectors. Vericel currently markets Epicel and Maci, two advanced cell therapy products, in the U.S. The company uses proprietary cell-processing technology to expand naturally occurring populations of cells derived from the patient’s own tissue. The company’s cell-manufacturing facility is located in Massachusetts.
Financial Highlights (FY 2024)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
Vericel Corp. In News
Company's Business Segments
- MACI : MACI is an autologous cellular scaffold product consisting of autologous cultured chondrocytes seeded onto a resorbable Type I/III porcine-derived collagen membrane.
- Epicel : Epicel is a permanent skin replacement for deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of TBSA
- NexoBrid : A topically-administered biological orphan product containing proteolytic enzymes
Applications/End User Industries
- Healthcare
BCC Research Beacon 